18FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study

Pulmonary Circulation

Volumn 1, Issue 4, 2011, Pages 448-455

  Hagan, Guy ^a   Southwood, Mark ^a   Treacy, Carmen ^a   Ross, Robert Mackenzie ^a   Soon, Elaine ^b   Coulson, James ^c   Sheares, Karen ^a   Screaton, Nicholas ^a   Pepke Zaba, Joanna ^a   Morrell, Nicholas W ^b   Rudd, James H F ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Inflammation; Positron emission tomography; Pulmonary arterial hypertension; Pulmonary artery; Right ventricle

Indexed keywords

EID: 84873716109     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.93543     Document Type: Article

References (40)

1. Brody JS, Stemmler EJ, DuBois AB. Longitudinal distribution of vascular resistance in the pulmonary arteries, capillaries and veins. J Clin Invest 1968;47:783-99.
2. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension, J Am Coll Cardiol 2009;54;S20-31.
3. Deng Z, Morse JH, Sleger SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44.
4. Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension, J Am Coll Cardiol 2009;54: S85-96.
5. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-31.
6. Quarck R, Nawrot T, Mayns B, Delcroix M. C-reactive protein: A new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:1211-8.
7. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-7.
8. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009;34:662-8.
9. Tuder RM, Voelkel NF. Pulmonary hypertension and infl ammation. J Lab Clin Med 1998;132:16-24.
10. von Haehling S, von Bardeleben RS, Kramm T, Thiermann Y, Niethammer M, Doehner W, et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol 2010;144:206-11.
11. Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Kilmas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: Ready for prime time? J Am Coll Cardiol 2010;55:2527-35.
12. Owen DR, Lindsay AC, Choudhury RP, Fayad ZA. Imaging of atherosclerosis. Annu Rev Med 2011;62:25-40.
13. Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent infl ammatory reactions. Am J Pathol 1982;107: 395-418.
14. Wang T, Marquardt C, Foker J. Aerobic glycolysis during lymphocyte proliferation. Nature 1976;261:702-5.
15. Munyon WH, Merchant DJ. The relation between glucose utilization, lactic acid production and utilization and the growth cycle of L strain fibroblasts. Exp Cell Res 1959;17:490-8.
16. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18 fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301-6.
17. Tahara T, Ichiya Y, Kuwabara Y, Otsuka M, Miyake Y, Gunasekera R, et al. High [18F]-fluorodeoxyglucose uptake in abdominal abscesses: A PET study. J Comput Assist Tomogr 1989;13:829-31.
18. Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis, Eur J Nucl Med Mol Imaging, 2009;36:632-9.
19. Keijsers RG, Grutters JC, van Velzen-Blad H, ven den Bosch JM, Oyen WJ, Verzijibergen FJ. (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging 2010;37: 1181-8.
20. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow up of large vessel vasculitis: An update. Rheumatology (Oxford) 2008;47:403-8.
21. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11.
22. Tahara N, Kai H, Yamagishi S, Mizogucki M, Nakaura H, Ishibashi M, et al. Vascular infl ammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. Am Coll Cardiol 2007;49:1533-9.
23. Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxygluclose positronemission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107-15.
24. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-31.
25. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.
26. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ. Att enuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998;351:726-7.
27. McMurthy MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, et al. Gene therapy targeting surviving selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. Clin Invest 2005;115:1479-91.
28. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. PNAS 2007;104:1342-437.
29. Oikawa M, Kagaya Y, Otani H, Sakuma M, Demachi J, Suzuki J, et al. Increased [18F]Fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 2005;45:1849-55.
30. National Pulmonary Hypertension Centers of UK and Ireland, Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland, Thorax 2008;63(Suppl 2):ii1-41.
31. Coulson JM, Rudd JH, Duckers JM, Rees JI, Shale DJ, Bolton CE, et al. Excessive aortic infl ammation in chronic obstructive pulmonary disease: An 18F-FDG PET pilot study. J Nucl Med 2010;51:1357-60.
32. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammatorion is highly reproducible:Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892-6.
33. Conti M. State of the art and challenges of time-of-flight PET. Phys Med 2009;25:1-11.
34. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a non-invasive measure of carotid plaque inflammation in patients, J Am Coll Cardiol 2006;48:1818-24.
35. Chen DL, Mintun MA, Schuster DP. Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury. J Nucl Med 2004;45:1583-90.
36. Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease:implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009;50:538-45.
37. Kluge R, Barthel H, Pankau H, Seese A, Schauer J, Wirtz H, et al. Different mechanisms for changes in glucose uptake of the right and left ventricular myocardium in pulmonary hypertension. J Nucl Med 2005;46:25-31.
38. Moore GW, Smith RL, Hutchins GM. Pulmonary artery atherosclerosis: Correlation with systemic atherosclerosis and hypertensive pulmonary vascular disease. Arch Pathol Lab Med 1982;106:378-80.
39. Hyafil F, Cornily J, Rudd JH, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: A comparison with 18F-FDG PET/CT and histology. J Nucl Med 2009;50:959-65.
40. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453-8.